Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study

BACKGROUND: Few data are available on the effects of age and comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD). AIMS: To evaluate the association between age and comorbidity with safety and effectiveness outcomes of vedolizumab and ustekinumab in IB...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Aliment Pharmacol Ther
Главные авторы: Asscher, Vera E. R., Biemans, Vince B. C., Pierik, Marieke J., Dijkstra, Gerard, Löwenberg, Mark, van der Marel, Sander, de Boer, Nanne K. H., Bodelier, Alexander G. L., Jansen, Jeroen M., West, Rachel L., Haans, Jeoffrey J. L., van Dop, Willemijn A., Weersma, Rinse K., Hoentjen, Frank, Maljaars, P. W. Jeroen
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2020
Предметы:
Efficacy and Safety of Biologics for Crohn's Disease
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539998/
https://ncbi.nlm.nih.gov/pubmed/32901983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.16073
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы